Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22430522 | 0.95 | HSD17B10 (0.45) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL22430538 | 0.85 | HSD17B10 (0.53) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL22430556 | 0.82 | HSD17B10 (0.50) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL22430526 | 0.80 | HSD17B10 (0.47) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL22430527 | 0.79 | CYP11B1 (0.48) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL29182831 | 0.79 | HSD17B10 (0.48) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL22430467 | 0.78 | MEN1 (0.56) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL22430483 | 0.77 | HSD17B10 (0.45) | HSD17B10KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL30157520 | 0.77 | LMNA (0.53) | HSD17B10KMT2ALMNAMEN1TSHR | |
| SCHEMBL7819571 | 0.77 | LMNA (0.51) | HSD17B10KMT2ALMNAMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934263-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200290979-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934263-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | HSD17B10 2778/4885KMT2A 3122/4885LMNA 2395/4885 |
| US-20200290979-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, ASIC1, TRPA1 | HSD17B10 2778/4885KMT2A 3122/4885LMNA 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.